Beckman Coulter has obtained clearance under the FDA's de novo pathway to market its ClearLLab Reagents. The tests facilitate the diagnosis of non-Hodgkin lymphoma, chronic and acute leukemia, myeloma and other rare blood cancers using flow cytometry.
Beckman Coulter secures FDA clearance for blood cancer diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.